Zealand Pharma A/S (OTCMKTS:ZLDPF) Trading Down 10.3% – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares traded down 10.3% during trading on Monday . The stock traded as low as $48.45 and last traded at $48.45. 200 shares traded hands during trading, a decline of 95% from the average session volume of 3,780 shares. The stock had previously closed at $54.00.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ZLDPF shares. Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. William Blair reaffirmed a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Finally, BNP Paribas Exane lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Three equities research analysts have rated the stock with a Strong Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Stock Performance

The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02. The company has a market cap of $3.44 billion, a PE ratio of 3.57 and a beta of 0.87. The company has a fifty day simple moving average of $45.90 and a two-hundred day simple moving average of $61.69.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.50. Zealand Pharma A/S had a return on equity of 41.50% and a net margin of 68.82%.The business had revenue of $5.33 million during the quarter, compared to the consensus estimate of $2.81 million. Analysts anticipate that Zealand Pharma A/S will post 2.95 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.